MRI in Transcatheter Aortic Valve Replacement Patients
Part of paid clinical trials in Cleveland, Ohio.
- Sponsor
- University Hospitals Cleveland Medical Center
- Study ID
- NCT05603026
- Status
- Recruiting
Conditions
- Aortic Valve Stenosis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 105 Years
- Healthy Volunteers
- Not accepted
Interventions
- Self-expanding valve (Medtronic Evolut FX) — DEVICEBioprothesis Medtronic Evolut FX supra-annular self-expanding valve
- Balloon-expanding valve (Edwards Sapien 3 Ultra RESILIA) — DEVICEBioprosthesis Edwards Sapien 3 Ultra valve
Study Details
The hypothesis is that SEV result in superior valvular hemodynamics (more pronounced during exercise) and exercise capacity relative to BEV. Furthermore, the hypothesis is that stress CMR will be able to demonstrate differences in these hemodynamic parameters. CMR will also provide refined assessment of paravalvular leak and its impact on ventricular function and on clinical outcomes.
Key Dates
- Start date
- Nov 21, 2023
- Status verified
- Dec 2025
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: TAVR using the self-expanding valve Evolut FXTranscatheter aortic valve replacement (TAVR) using the bioprosthesis Medtronic Evolut FX supra-annular self-expanding valve
- Active Comparator: TAVR using the balloon-expandable valve Sapien 3 Ultra RESILIATranscatheter aortic valve replacement (TAVR) using the bioprosthesis Edwards Sapien 3 Ultra valve
Primary Outcome Measure
Effective orifice area (EOA) [ Time Frame: Baseline, 30-days and 1-year ]
Central Contacts
- Luis Dallan, MD216-844-1000
- LaStasha Cowan216-844-1000
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | 44106 |
Find similar trials in Cleveland, OH
By research site
Related Studies
- PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVRRecruiting · Edwards Lifesciences · Huntsville, Alabama
- ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic ValvesRecruiting · Edwards Lifesciences · Newport Beach, California
- Effect of Fetal Aortic Valvuloplasty on OutcomesRecruiting · Queen Silvia Children's Hospital, Gothenburg, Sweden · San Francisco, California
- Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVRRecruiting · Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · San Francisco, California